

Figure S1. Schematic representation of hiPSC induction. Dermal fibroblasts were reprogrammed with Yamanaka's cocktail (Oct4, Sox2, Klf4, c-Myc) into induced pluripotent stem cells. HiPSC clones were generated in 18 days and then amplified to passage 15.




Figure S2. hiPSC generated from a healthy control (A1- P1) and a CMT2 patient (A2-P2). HiPSC colonies have a typical morphology (A1, A2), with a nucleus/cytoplasm ratio of 1:1. Embryoid bodies (B1, B2) could be differentiated into cell types from the three embryonic germ layers following spontaneous differentiation (C1, C2) and labelling with α -SMA ((E1, E2) mesoderma), PAX6 ((F1, F2) ectoderma), and Sox17 ((G1,G2) endoderma). HiPSCs expressed pluripotency markers, including Nanog, Oct3/4, and Sox2 (I1-P1, I2, P2), were positive for alkaline phosphatase (D1, D2), and had normal karyotypes (H1, H2).




Figure S3. ChAT immunostaining performed at d15 on neuronal progenitors from a healthy control.




Figure S4. Ki-67 immunostaining performed at d0 (iPSC stage A-B, E) and d15 (neuronal progenitor C-D, E) from a healthy control. (E) Histograms showed the KI-67 positives cells between hiPSCs (d0) and neuronal progenitor (d15) from a healthy control (Student T Test, $n = 4$ to 7 , $***p < 0.001$).




Figure S5. Factors involved in dorsal-ventral polarity during cord differentiation (A), factors involved in antero-posterior differentiation during neurulation (B), and MN markers during differentiation (C) adapted from Casarosa et al., 2013 and Davis-Dusenbery et al., 2014 [35,37]